Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort) (proNICU)

November 28, 2018 updated by: Andreas Meisel, Charite University, Berlin, Germany
This study examines the prognostic properties of immune parameters, clinical scores, electrophysiological tests (eeg, ssep, emg, eng) and functional imaging for the prediction of functional outcome one year after treatment on a neurological intensive care unit.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

46

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany
        • Charite University (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with severe neurological diseases treated on a neurological intensive care unit

Description

Inclusion Criteria:

  • severe neurological disease making treatment on a neurological intensive care unit necessary
  • age ≥ 18
  • consent by the patient or the legal representative

Exclusion Criteria:

  • participation in an interventional trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
severe neurological diseases
Patients with severe neurological diseases treated on the neurological intensive care unit

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Predictive properties of immune parameters (IL6, IL10, mHLA-DR) for functional outcome one year after symptom onset
Time Frame: one year after symptom onset
To evaluate of the predictive properties of immune parameters (IL6, IL10, mHLA-DR) for functional outcome one year after symptom onset
one year after symptom onset

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate of the predictive properties of clinical scores for functional outcome one year after symptom onset
Time Frame: one year after symptom onset
To evaluate of the predictive properties of clinical scores for functional outcome one year after symptom onset
one year after symptom onset
To evaluate of the predictive properties of electrophysiological measurements one year after symptom onset
Time Frame: one year after symptom onset
To evaluate of the predictive properties of electrophysiological measurements one year after symptom onset
one year after symptom onset
To evaluate of the predictive properties of conventional (DTI) and functional imaging (resting state) one year after symptom onset
Time Frame: one year after symptom onset
To evaluate of the predictive properties of conventional (DTI) and functional imaging (resting state) one year after symptom onset
one year after symptom onset
Transcriptome analyses
Time Frame: one year after symptom onset
To perform transcriptome analyses to identify new biomarkers which may predict the one year- neurological outcome
one year after symptom onset
Predictive properties of immune parameters in the cerebrovascular fluid for functional outcome one year after symptom onset
Time Frame: one year after symptom onset
To evaluate of the predictive properties of immune parameters in the cerebrovascular fluid for functional outcome one year after symptom onset
one year after symptom onset
Quality of life and occurence of depression in patients one year after symptom onset
Time Frame: one year after symptom onset
To investigate the quality of life and the occurence of depression in patients one year after symptom onset
one year after symptom onset
Quality of life and the occurence of depression and burnout syndrome in relatives
Time Frame: one year after symptom onset
To investigate the quality of life and the occurence of depression and burnout syndrome in relatives of patients treated on the neurological intensive care unit one year after symptom onset
one year after symptom onset

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

October 3, 2016

Study Completion (Actual)

October 3, 2016

Study Registration Dates

First Submitted

October 31, 2011

First Submitted That Met QC Criteria

November 1, 2011

First Posted (Estimate)

November 2, 2011

Study Record Updates

Last Update Posted (Actual)

November 29, 2018

Last Update Submitted That Met QC Criteria

November 28, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurological Diseases

3
Subscribe